

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 September 2007 (13.09.2007)

PCT

(10) International Publication Number
WO 2007/102770 A1

- (51) **International Patent Classification:**
A61K 31/497 (2006.01) *A61P 19/10* (2006.01)
- (21) **International Application Number:**
PCT/SE2007/000216
- (22) **International Filing Date:** 6 March 2007 (06.03.2007)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
60/780,252 8 March 2006 (08.03.2006) US
- (71) **Applicant** (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).
- (72) **Inventors; and**
- (75) **Inventors/Applicants** (for US only): **BERG, Anna-Lena** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **BHAT, Ratan** [US/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE).
- (74) **Agent:** **ASTRAZENECA AB**; Global Intellectual Property, S-151 85 Södertälje (SE).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, **BR**, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, **HR**, HU, **ID**, IL, IN, IS, **JP**, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:
— with international search report

- (48) **Date of publication of this corrected version:**
31 January 2008

- (15) **Information about Correction:**
see PCT Gazette No. 05/2008 of 31 January 2008

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) **Title:** GSK-3 INHIBITORS FOR THE TREATMENT OF OSTEOPOROSIS



(57) **Abstract:** The present invention relates to a new use of a compound of the formula (I) wherein R₁ is NH₂, piperazin-1-yl, 4-methylpiperazin-1-yl, 4-methyl-1,4-diazepan-1-yl or 4-ethylpiperazin-1-yl; R₂ is hydrogen, fluoro, CH₃, CH₂CH₃, OCH₃, CF₃ or OCF₃; R₃ is hydrogen, CH₃ or fluoro; as a free base or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention and/or treatment of bone-related disorders, osteoporosis and increasing bone formation, bone mineral density. The present invention further relates to a method of prevention and/or treatment of these disorders.

WO 2007/102770 A1